Welcome to our dedicated page for Arcutis Biotherapeutics news (Ticker: ARQT), a resource for investors and traders seeking the latest updates and insights on Arcutis Biotherapeutics stock.
Arcutis Biotherapeutics reports company developments as a commercial-stage biopharmaceutical company focused on immuno-dermatology and medical dermatology. Its recurring updates center on ZORYVE (roflumilast) cream and foam, a topical PDE4 inhibitor portfolio used across inflammatory skin diseases including plaque psoriasis, atopic dermatitis, and seborrheic dermatitis.
Company news commonly covers ZORYVE net product revenue, demand trends for branded non-steroidal topical treatments, clinical data from dermatology studies, FDA submissions tied to potential label expansion, medical-meeting presentations, guideline references, sales-force and commercial updates, conference participation, and equity grants made under Nasdaq inducement-grant rules.
Arcutis Biotherapeutics reported third-quarter results with net revenues of $0.7 million from the launch of ZORYVE for plaque psoriasis in August 2022. The company achieved coverage for ZORYVE from a leading pharmacy benefit manager and a national health plan. It completed the enrollment for two pivotal Phase 3 trials for atopic dermatitis, with topline data expected by year-end. Additionally, Arcutis acquired Ducentis BioTherapeutics, enhancing its pipeline. As of September 30, 2022, the company holds approximately $480 million in cash and equivalents.
Arcutis Biotherapeutics (Nasdaq: ARQT) announced a conference call and webcast on November 8, 2022, at 5:00 p.m. ET to discuss its Q3 2022 financial results. The press release will be available after U.S. market close on the same day. Arcutis specializes in developing innovative therapies for immune-mediated dermatological diseases, utilizing a robust development platform with multiple clinical programs targeting conditions like scalp psoriasis and atopic dermatitis. For more details, visit www.arcutis.com.
Summary not available.
Arcutis Biotherapeutics (Nasdaq: ARQT) announced the grant of 32,300 restricted stock units and options for 85,800 shares to nine new employees, as approved by its Compensation Committee. These awards were made under the 2022 Inducement Plan, with the grant date set on September 1, 2022. The restricted stock units vest over four years, while the stock options have a ten-year term and an exercise price of $19.20 per share, equal to the closing price on October 3, 2022. This initiative aims to attract key talent as part of Arcutis’ ongoing growth in immuno-dermatology.
Arcutis Biotherapeutics announced positive results from the Phase 3 ARRECTOR trial of roflumilast foam 0.3% for scalp and body psoriasis. The study met both co-primary endpoints: 67.3% of participants achieved S-IGA Success versus 28.1% with a vehicle, while 46.5% achieved B-IGA Success compared to 20.8%. Roflumilast foam demonstrated a favorable safety profile, with a majority completing the trial. Arcutis plans to file a New Drug Application based on these results, highlighting the foam's potential to address unmet needs in psoriasis treatment.
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) announced positive results from two pivotal Phase 3 studies published in JAMA, evaluating its roflumilast cream for chronic plaque psoriasis treatment. In these studies, 40% of treated patients achieved Investigator Global Assessment success at eight weeks, significantly outperforming the vehicle group. Key findings include around 70% achieving intertriginous-IGA success and approximately 40% reaching PASI-75. Roflumilast showed rapid improvements in itch and plaque clearance, with a favorable safety profile.
Arcutis Biotherapeutics has announced positive data from the STRATUM Phase 3 trial of its investigational roflumilast foam for treating seborrheic dermatitis in adults and children 9 and older. The study achieved its primary endpoint, with 80.1% of patients achieving 'IGA Success' compared to 59.2% with vehicle (P<0.0001). Over 60% experienced significant itch relief by week 8. All secondary endpoints also showed statistically significant improvements. Roflumilast foam was well-tolerated, showing no serious adverse events, and an NDA submission is planned for Q1 2023.
LifeArc today announced the acquisition of its portfolio company Ducentis BioTherapeutics by Arcutis Biotherapeutics (NASDAQ: ARQT) for up to $400 million. The deal includes a $16 million upfront cash payment and Arcutis stock valued at $14 million, plus contingent payments linked to development success. Ducentis' lead asset, DS-234, targets the underserved atopic dermatitis market.
Arcutis aims to leverage its expertise in dermatology to accelerate the clinical development of DS-234, enhancing its innovative treatment pipeline.
Arcutis announced the acquisition of Ducentis BioTherapeutics for approximately $30 million in cash and stock, targeting the development of DS-234, a promising treatment for atopic dermatitis. The growing market shows a significant unmet need, and DS-234 aims to be a best-in-class option, complementing Arcutis’ existing therapies. The acquisition leverages Arcutis’ dermatology expertise, with the goal of advancing innovative therapies to address critical patient needs in immune-mediated diseases.
Arcutis Biotherapeutics (Nasdaq: ARQT) announced the presentation of four abstracts for its topical roflumilast program at the EADV Congress from September 7-10, 2022. Key highlights include the oral presentation of data from the STRATUM Phase 3 trial of roflumilast foam in seborrheic dermatitis, scheduled for September 9. The company emphasizes the unmet need for non-steroidal treatments, showcasing the safety and efficacy of ZORYVE (roflumilast cream) for plaque psoriasis. This initiative underscores Arcutis' commitment to addressing dermatological conditions.